Aligos therapeutics presents positive data at the easl congress 2025

South san francisco, calif., may 08, 2025 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the european association for the study of the liver (easl) congress 2025, being held may 7 – 10, 2025 in amsterdam, netherlands.
ALGS Ratings Summary
ALGS Quant Ranking